• Home
• People
• Bio
• Nilesh Chande

Nilesh Chande

Dr. Nilesh Chande is an Associate Professor of Medicine at Western University, and past Director of the Gastroenterology Training Program at Western. He is also the past Coordinating Editor of the Cochrane Library Inflammatory Bowel Disease and Functional Bowel Disorders Review Group. He completed his MD, his Internal Medicine residency and his Gastroenterology fellowship at Western University. His clinical interests include inflammatory bowel disease and general gastroenterology. His research interests include inflammatory bowel disease and evidence-based gastroenterology practice.

Selected Publications

Al-Judaibi B, Schwarz UI, Huda N, Dresser GK, Gregor JC, Ponich T, Chande N, Mosli M, Kim RB. Genetic predictors of azathioprine toxicity and clinical response in patients with inflammatory bowel disease. J Popul Ther Clin Pharmacol 2016;23(1):e26-36. PMID 26950049.

Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;5:CD000478. PMID 27192092.

Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG. The next wave of biological agents for the treatment of IBD:  evidence from Cochrane Reviews. Inflamm Bowel Dis 2016;22(7):1737-43. PMID 27306074.

Patton PH, Parker CE, MacDonald JK, Chande N. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2016;7:CD000299. PMID 27444319.

Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2016;10:CD000545. PMID 27783843.

Kwapisz L, Gregor J, Chande N, Yan B, Ponich T, Mosli M. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scan J Gastroenterol 2017;52(8):846-50. PMID 28423962.

Chande N. Al Yatama N. Bhanji T, Nguyen TM, McDonald JW, MacDonald JK. Interventions for treating lymphocytic colitis. Cochrane Database Syst Rev 2017;7:CD006096. PMID 28702956.

Kafil TS, Nguyen TM, Patton PH, MacDonald JK, Chande N, McDonald JW. Interventions for treating collagenous colitis. Cochrane Database Syst Rev 2017;(11):CD003575.  PMID 29127772.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton, M, McIntosh K, Teft WA, Kim RB. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2018;47(5):615-620. PMID 29270995.

Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2018 Apr 1;CD010410. PMID 29607497.

Ma C, Dutton SJ, Cipriano LE, Singh S, Parker CE, Nguyen TM, Guizzetti L, Gregor JC, Chande N, Hindryckx P, Feagan BG, Jairath V. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. Aliment Pharmacol Ther 2018;48(2):114-126. PMID 29851091.

Rofaiel R, Chande N. Biologic agents in inflammatory bowel disease - quality of internet website information. Saudi J Gastroenterol 2018;24(6):336-41. PMID 30004043.

Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of ulcerative colitis. Cochrane Database Syst Rev 2018 Nov 8;11:CD012954. PMID 30406638.

Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of Crohn's disease. Cochrane Database Syst Rev 2018 Nov 8;11:CD012853. PMID 30407616.

Riviere P, Munch A, Michetti P, Chande N, de Hertogh G, Schoeters P, Ferrante M, Vermeire S, Van Assche G. Vedolizumab in refractory microscopic colitis: an international case series. J Crohn's Colitis 2019; 13(3):337-40.PMID 30329034.

Ma, Guizzetti, L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49(4):364-74. PMID 30569460.

East JE, Boyapati RK, Torres J, Parker CE, MacDonald JK, Chande N, Feagan BG. Controversies in inflammatory bowel disease: exploring clinical dilemmas using Cochrane reviews. Inflamm Bowel Dis 2019;25(3):472-8. PMID 30789982.

Wilson A, Urquhart BL, Ponich T, Chande N, Gregor JC, Beaton M, Kim RB. Crohn's disease is associated with decreased CYP3A4 and P-glycoprotein protein expression. Mol Pharm 2019;16(9):4059-64. PMID 31393129.

Chande N, Costello SP, Limketkai BN, Parker CE, Nguyen TM, Macdonald JK, Feagan BG. Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2020 May 12;26(6):843-851. PMID 31560744.

Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of Crohn's disease and ulcerative colitis: Evidence from Cochrane Reviews.  Inflamm Bowel Dis 2020 Mar 4;26(4). PMID 31613959.

Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan B, Gregor JC, Khanna R. Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of combination biologic and antirejection therapy post-liver transplantation in patients with inflammatory bowel disease. Inflamm Bowel Dis 2020 May 12;26(6):949-959. PMID 31665288. 

Virine B, Chande N, Driman DK. Biopsies from ascending and descending colon are sufficient for diagnosis of microscopic colitis. Clin Gastroenterol Hepatol 2020 Aug;18(9):2003-2009. PMID 32109628.

Ayoub A, Jairath V. Aldraiweesh S, Khanna R, Gregor J, Chande N. Safety of biologic therapy in octogenarians and nonagenarians in Ontario:  a case series in Ontario. Inflamm Bowel Dis 2020 (online ahead of print). PMID 32651999.